Clinical features and the traditional Chinese medicine therapeutic characteristics of 293 COVID-19 inpatient cases
- PMID: 32926319
- PMCID: PMC7488634
- DOI: 10.1007/s11684-020-0803-8
Clinical features and the traditional Chinese medicine therapeutic characteristics of 293 COVID-19 inpatient cases
Abstract
Coronavirus disease 2019 (COVID-19) is now pandemic worldwide and has heavily overloaded hospitals in Wuhan City, China during the time between late January and February. We reported the clinical features and therapeutic characteristics of moderate COVID-19 cases in Wuhan that were treated via the integration of traditional Chinese medicine (TCM) and Western medicine. We collected electronic medical record (EMR) data, which included the full clinical profiles of patients, from a designated TCM hospital in Wuhan. The structured data of symptoms and drugs from admission notes were obtained through an information extraction process. Other key clinical entities were also confirmed and normalized to obtain information on the diagnosis, clinical treatments, laboratory tests, and outcomes of the patients. A total of 293 COVID-19 inpatient cases, including 207 moderate and 86 (29.3%) severe cases, were included in our research. Among these cases, 238 were discharged, 31 were transferred, and 24 (all severe cases) died in the hospital. Our COVID-19 cases involved elderly patients with advanced ages (57 years on average) and high comorbidity rates (61%). Our results reconfirmed several well-recognized risk factors, such as age, gender (male), and comorbidities, as well as provided novel laboratory indications (e.g., cholesterol) and TCM-specific phenotype markers (e.g., dull tongue) that were relevant to COVID-19 infections and prognosis. In addition to antiviral/antibiotics and standard supportive therapies, TCM herbal prescriptions incorporating 290 distinct herbs were used in 273 (93%) cases. The cases that received TCM treatment had lower death rates than those that did not receive TCM treatment (17/273 = 6.2% vs. 7/20= 35%, P = 0.0004 for all cases; 17/77= 22% vs. 7/9= 77.7%, P = 0.002 for severe cases). The TCM herbal prescriptions used for the treatment of COVID-19 infections mainly consisted of Pericarpium Citri Reticulatae, Radix Scutellariae, Rhizoma Pinellia, and their combinations, which reflected the practical TCM principles (e.g., clearing heat and dampening phlegm). Lastly, 59% of the patients received treatment, including antiviral, antibiotics, and Chinese patent medicine, before admission. This situation might have some effects on symptoms, such as fever and dry cough. By using EMR data, we described the clinical features and therapeutic characteristics of 293 COVID-19 cases treated via the integration of TCM herbal prescriptions and Western medicine. Clinical manifestations and treatments before admission and in the hospital were investigated. Our results preliminarily showed the potential effectiveness of TCM herbal prescriptions and their regularities in COVID-19 treatment.
Keywords: COVID-19; clinical features; traditional Chinese medicine.
Conflict of interest statement
Zixin Shu, Yana Zhou, Kai Chang, Jifen Liu, Xiaojun Min, Qing Zhang, Jing Sun, Yajuan Xiong, Qunsheng Zou, Qiguang Zheng, Jinghui Ji, Josiah Poon, Baoyan Liu, Xuezhong Zhou, and Xiaodong Li declare that they have no conflict of interest. This study was approved by the ethics review board of Hubei Provincial Hospital of Traditional Chinese Medicine (HBZY2020-C01-01). Written consent was waived due to the retrospective nature. This study was reported according to STROBE (The Strengthening the Reporting of Observational Studies in Epidemiology).
Similar articles
-
Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial.Trials. 2020 Dec 23;21(1):1029. doi: 10.1186/s13063-020-04970-3. Trials. 2020. PMID: 33357239 Free PMC article.
-
[Medication law and mechanism of traditional Chinese medicine in prevention and treatment of epidemic diseases: based on traditional Chinese medicine theory of cold pestilence].Zhongguo Zhong Yao Za Zhi. 2022 Sep;47(17):4765-4777. doi: 10.19540/j.cnki.cjcmm.20220528.501. Zhongguo Zhong Yao Za Zhi. 2022. PMID: 36164884 Chinese.
-
A real-world study of the differences in Traditional Chinese Medicine diagnosis and treatment rules for coronavirus disease 2019 between Northern and Southern China.J Tradit Chin Med. 2024 Aug;44(4):822-829. doi: 10.19852/j.cnki.jtcm.2024.04.004. J Tradit Chin Med. 2024. PMID: 39066543 Free PMC article.
-
Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis.Pharmacol Res. 2020 Oct;160:105056. doi: 10.1016/j.phrs.2020.105056. Epub 2020 Jul 2. Pharmacol Res. 2020. PMID: 32622723 Free PMC article.
-
Traditional Chinese Medicine as a complementary therapy in combat with COVID-19-A review of evidence-based research and clinical practice.J Adv Nurs. 2021 Apr;77(4):1635-1644. doi: 10.1111/jan.14673. Epub 2020 Nov 29. J Adv Nurs. 2021. PMID: 33174654
Cited by
-
Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China.Front Public Health. 2022 Oct 24;10:1038017. doi: 10.3389/fpubh.2022.1038017. eCollection 2022. Front Public Health. 2022. PMID: 36353282 Free PMC article.
-
Microbial Characteristics of Common Tongue Coatings in Patients with Precancerous Lesions of the Upper Gastrointestinal Tract.J Healthc Eng. 2022 Apr 18;2022:7598427. doi: 10.1155/2022/7598427. eCollection 2022. J Healthc Eng. 2022. PMID: 35480154 Free PMC article.
-
Pathophysiology and Management of Tongue Involvement in COVID-19 Patients.Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):3235-3238. doi: 10.1007/s12070-021-03052-3. Epub 2022 Jan 6. Indian J Otolaryngol Head Neck Surg. 2022. PMID: 35013709 Free PMC article.
-
Transcriptomic and biochemical insights into key gene networks driving bulbil development of Pinellia ternata (Thunb.) Breit.PLoS One. 2025 Feb 11;20(2):e0314396. doi: 10.1371/journal.pone.0314396. eCollection 2025. PLoS One. 2025. PMID: 39932947 Free PMC article.
-
Clinical data mining reveals Gancao-Banxia as a potential herbal pair against moderate COVID-19 by dual binding to IL-6/STAT3.Comput Biol Med. 2022 Jun;145:105457. doi: 10.1016/j.compbiomed.2022.105457. Epub 2022 Mar 26. Comput Biol Med. 2022. PMID: 35366469 Free PMC article.
References
-
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features ofpatients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. - PMC - PubMed
-
- Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523. - PMC - PubMed
-
- Chan KW, Wong VT, Tang SCW. COVID-19: an update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western medicine for the management of 2019 novel coronavirus disease. Am J Chin Med. 2020;48(3):737–762. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical